VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 559 filers reported holding VALEANT PHARMACEUTICALS INTL in Q3 2015. The put-call ratio across all filers is 1.96 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $0 | – | 34 | 0.0% | 0.00% | – |
| Q1 2018 | $0 | -100.0% | 34 | -39.3% | 0.00% | – |
| Q4 2017 | $1,000 | – | 56 | 0.0% | 0.00% | – |
| Q3 2017 | $0 | – | 56 | 0.0% | 0.00% | – |
| Q2 2017 | $0 | – | 56 | 0.0% | 0.00% | – |
| Q1 2017 | $0 | – | 56 | 0.0% | 0.00% | – |
| Q4 2016 | $0 | -100.0% | 56 | 0.0% | 0.00% | – |
| Q3 2016 | $1,000 | 0.0% | 56 | 0.0% | 0.00% | – |
| Q2 2016 | $1,000 | -100.0% | 56 | -99.8% | 0.00% | -100.0% |
| Q3 2015 | $5,708,000 | -33.3% | 32,000 | -16.9% | 0.04% | -26.0% |
| Q2 2015 | $8,552,000 | -14.7% | 38,500 | -23.8% | 0.05% | -13.8% |
| Q1 2015 | $10,030,000 | +15.8% | 50,500 | -16.5% | 0.06% | +18.4% |
| Q4 2014 | $8,658,000 | -29.0% | 60,500 | -34.9% | 0.05% | -31.0% |
| Q3 2014 | $12,188,000 | -57.7% | 92,900 | -59.3% | 0.07% | -61.0% |
| Q2 2014 | $28,780,000 | +67.3% | 228,200 | +74.9% | 0.18% | +61.1% |
| Q1 2014 | $17,203,000 | -30.9% | 130,500 | -38.5% | 0.11% | -31.5% |
| Q4 2013 | $24,892,000 | – | 212,031 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chou Associates Management | 1,648,992 | $38,323,000 | 14.52% |
| Paulson & Co. | 20,839,035 | $484,299,000 | 9.89% |
| MILLER VALUE PARTNERS, LLC | 4,999,064 | $116,178,000 | 4.34% |
| GoldenTree Asset Management | 1,140,205 | $26,498,000 | 4.21% |
| Pomelo Capital LLC | 1,760,000 | $40,902,000 | 4.00% |
| Bruce & Co., Inc. | 860,000 | $19,986,000 | 3.98% |
| ValueAct Holdings | 18,033,149 | $419,090,000 | 3.79% |
| Stanley Capital Management, LLC | 318,400 | $7,400,000 | 3.25% |
| Kazazian Asset Management, LLC | 134,784 | $3,132,000 | 2.87% |
| Phoenix Investment Adviser LLC | 58,400 | $1,357,000 | 2.48% |